AIM ImmunoTech Inc. (AIM) Completes Dosing; Phase 2 Results Expected Q1 2027

AIM ImmunoTech completed dosing in its Phase 2 DURIPANC study. The company expects topline clinical benefit results in Q1 2027 and survival analyses in Q3 2027, according to its press release.

Original reporting
Published Nov 13, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:44 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AIM ImmunoTech Inc. (AIM) Completes Dosing; Phase 2 Results Expected Q1 2027 — source image
Decision brief

The 30-second read

$AIMNeutralLow
01

Why it matters

The completion of dosing is a standard trial milestone; price movement will depend on the forthcoming efficacy and survival data.

02

Market read

The news is a modest update for AIM shareholders; broader market impact is limited.

03

What to watch

Potential partnership or licensing discussions could arise after data readout, affecting valuation.

Relevance 7/10Novelty 6/10Timing: future Q1 2027 readout

Background

AIM ImmunoTech is a Nasdaq‑listed biotech developing Ampligen for immunotherapy. The Phase 2 DURIPANC study has now completed dosing.

Company-level read

Ticker impact

$AIMNeutralHigh confidence
Context

AIM ImmunoTech announced completion of Phase 2 dosing, a new milestone for its Ampligen trial.

Expected impact

likely modest pressure as the market prices in the pending data readout

Evidence & confidence

No efficacy results are available yet, so the news does not provide a clear upside or downside.

Market effects

May keep biotech sector attention on upcoming trial readouts but no immediate sector shift.

Limited to U.S. biotech investors; no broader regional effect.

Minimal global impact; only relevant to investors tracking immunotherapy pipelines.

Counterpoint

Some traders may short on the basis that the lack of data could lead to disappointment.

Key entities

  • AIM ImmunoTech Inc.

    Biotech firm developing Ampligen.

Related articles

$AIMLow

AIM ImmunoTech completes dosing in pancreatic cancer trial

AIM ImmunoTech (AIM) completed dosing in its Phase 2 DURIPANC trial for pancreatic cancer, with results expected in 2027. The trial tests Ampligen with AstraZeneca's Imfinzi. AIM reported Q3 2026 cash of $6.9M, R&D expenses of $846K, and a net loss of $3.1M. The company secured patents for Ampligen combinations and repaid a promissory note.